Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 8.8% in January

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 106,100 shares, a decrease of 8.8% from the January 15th total of 116,400 shares. Based on an average daily trading volume, of 158,300 shares, the short-interest ratio is presently 0.7 days. Currently, 0.4% of the company’s stock are sold short.

Institutional Trading of Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC grew its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 115,386 shares of the company’s stock after acquiring an additional 28,773 shares during the quarter. FMR LLC owned about 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. Institutional investors own 86.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Stock Up 2.8 %

Shares of NASDAQ:BOLT traded up $0.01 during midday trading on Monday, reaching $0.50. The company had a trading volume of 225,538 shares, compared to its average volume of 128,879. The stock has a market cap of $19.20 million, a PE ratio of -0.29 and a beta of 0.95. Bolt Biotherapeutics has a 1-year low of $0.46 and a 1-year high of $1.56. The business’s 50 day moving average price is $0.52 and its 200 day moving average price is $0.60. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.